Exhibit 99.1 Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $45.3 million in 1Q and$95.9 million since August First patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lung Received Fast Track Designations for both inhaled and intratumoral KB707 Strong balance sheet with $622.3 million in cash and investments PITTSBURGH, May 6, 2024 (GLOBE NEWSWIRE) – Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), ...